Guaifenesin, the generic for Mucinex, contains the known carcinogen benzene, but Walgreens packaging does not disclose this, according to court documents obtained by Becker’s. The plaintiffs said they would not have purchased or would have paid less for the guaifenesin if they had known about the cancer-causing agent.
The Walgreens customers seek compensatory, statutory and punitive damages.
In the manufacturing of extended-release guaifenesin, thickening agents might contain benzene, according to Bloomberg. For years, the FDA has warned drugmakers about the risk of benzene contamination, but at least a dozen medications are made with thickening agents — carbomers — that might contain benzene.
By 2026, the United States Pharmacopeia plans to omit carbomers that are manufactured with benzene, Bloomberg reported.
Becker’s has reached out to Walgreens for comment and will update this article if more information becomes available.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
